Phosphoenolpyruvate as a Regulator of Inflammaging via cGAS-STING Inhibition

Study Background and Research Question

Aging is accompanied by a progressive decline in physiological function and an increased burden of chronic diseases. One hallmark of this process is chronic, low-grade inflammation—termed 'inflammaging'—which disrupts tissue homeostasis and underlies neurodegenerative, cardiovascular, and metabolic disorders. Despite the clear association between inflammation and aging, the intrinsic adaptive mechanisms that might counteract age-associated inflammation remain poorly defined. The reference study focuses on the glycolytic metabolite phosphoenolpyruvate (PEP), investigating whether it functions as an endogenous modulator of inflammation through the cGAS–STING pathway and thereby contributes to healthy aging.

Key Innovation from the Reference Study

The central innovation of this research is the identification of PEP as an evolutionarily conserved, adaptive metabolite that restricts cGAS-driven inflammation. Unlike previous studies that emphasized exogenous anti-inflammatory agents or broad metabolic interventions, this work demonstrates that PEP naturally accumulates in the aging systemic milieu and acts as an endogenous inhibitor of the cGAS–STING pathway. By competitively binding to cGAS, PEP prevents its hyperactivation and the consequent amplification of type I interferon responses that drive chronic inflammation. This insight provides a mechanistic link between central carbon metabolism and inflammation control in aging, opening new avenues for targeting metabolic intermediates as modulators of inflammatory signaling.

Methods and Experimental Design Insights

The research employed a combination of longitudinal metabolomics, genetic and pharmacological interventions, and functional assays in both murine and human systems. Key methodological highlights include:

• Longitudinal metabolite profiling: Analysis of plasma and tissue samples from mice and humans across the lifespan to characterize PEP trajectories.
• Functional manipulation: Genetic models and pharmacological inhibitors were used to modulate PEP levels and glycolytic flux, followed by assessment of inflammaging phenotypes.
• Inflammatory pathway interrogation: In vitro and in vivo assays examined the activation state of the cGAS–STING pathway in response to PEP manipulation.
• Behavioral and pathological assessment: Cognitive function and neuroinflammation were evaluated in mouse models of Alzheimer’s disease upon PEP supplementation.

This integrative approach allowed the researchers to establish causality between PEP accumulation, cGAS–STING activity, and downstream inflammatory and aging phenotypes.

Core Findings and Why They Matter

The study’s major findings include:

• Biphasic PEP trajectory: Both murine and human samples revealed that PEP levels initially accumulate in early and mid-life, followed by a decline with advanced age.
• PEP as an endogenous cGAS inhibitor: Mechanistic assays demonstrated that PEP directly binds cGAS, reducing its ability to sense cytosolic DNA and activate the STING pathway.
• Functional consequences of PEP modulation: Inhibition or depletion of PEP in aged mice led to heightened inflammation, accelerated aging phenotypes, and impaired cognitive function. Conversely, PEP supplementation before its natural decline ameliorated these effects and improved healthspan indicators.
• Relevance to neurodegeneration: PEP administration reduced neuroinflammation and improved cognitive performance in an Alzheimer’s disease mouse model, suggesting translational potential for neurodegenerative disease research.
• Correlation in humans: High systemic PEP levels in older adults correlated strongly with lower inflammatory markers and healthier physiological traits.

Collectively, these results position PEP as a critical metabolic checkpoint in the regulation of age-associated inflammatory signaling, with direct implications for the design of metabolic and anti-inflammatory interventions.

Comparison with Existing Internal Articles

The present findings align with and extend the conceptual framework discussed in internal reviews such as "Hexose Diphosphate: Integrative Probe in Metabolic and Inflammation Research". That article underscores the value of glycolytic intermediates, including hexose diphosphate and related compounds, as tools for dissecting energy homeostasis and inflammatory modulation. The current study's demonstration of PEP as a natural inflammatory signaling modulator refines this perspective by revealing a direct metabolic-inflammation interface. Similarly, "Hexose Diphosphate: Bridging Metabolism and Inflammation Research" emphasizes the translational relevance of such metabolites in tissue injury and aging models, a theme that is now bolstered by the mechanistic evidence connecting PEP to cGAS–STING regulation. For workflows focused specifically on metabolic flux and cardiovascular or neurodegenerative models, further detail is available in "Hexose Diphosphate: Applied Workflows for Metabolic Flux & Inflammation".

Limitations and Transferability

While the evidence for PEP’s role in modulating cGAS-mediated inflammation is compelling, several caveats must be considered. Most notably, the study’s intervention protocols focused on pre-decline supplementation in aged mice, which may not fully recapitulate the complexity of human aging or chronic disease states. The precise dynamics and tissue-specific distribution of PEP, as well as potential off-target effects of sustained metabolic manipulation, warrant further investigation. Moreover, while strong correlations between PEP levels and healthy aging markers were observed in human cohorts, causal relationships remain to be established in clinical settings. Finally, the transferability of findings to other glycolytic intermediates, such as hexose diphosphate, should be approached with mechanistic caution, as these molecules may exhibit divergent regulatory properties within central carbon metabolism and inflammatory signaling cascades.

Protocol Parameters

• PEP supplementation (mouse models): Initiate administration prior to the observed physiological decline in PEP levels; specific dosing and timing are detailed in the reference study.
• Inflammatory marker assessment: Quantify cGAS–STING pathway components and downstream cytokine expression in plasma and relevant tissues.
• Cognitive and behavioral endpoints: Apply validated tests for memory and neuroinflammation when modeling neurodegenerative disease.
• Metabolite profiling: Use targeted metabolomics to monitor PEP (and potentially hexose phosphate) trajectories across experimental groups.
• Workflow adaptation: For studies focusing on energy homeostasis or enzymatic regulation of carbohydrate metabolism, consider integrating hexose diphosphate as a metabolic probe in parallel to PEP to dissect pathway-specific effects.

Why this cross-domain matters, maturity, and limitations

The bridge between metabolic flux and inflammatory signaling—highlighted by the PEP–cGAS interaction—underscores the translational significance of metabolic intermediates in geroscience and neuroinflammation research. While the mechanistic evidence is robust in preclinical models, clinical translation will require careful validation of dosing, safety, and efficacy parameters. Furthermore, although hexose diphosphate and PEP are both glycolytic intermediates, their direct comparability as modulators of cGAS–STING remains hypothetical, necessitating distinct experimental verification.

Research Support Resources

To facilitate further investigation into metabolic regulation of inflammation and aging, researchers can employ well-characterized metabolic probes such as hexose diphosphate (SKU M1436), a water-soluble hexose phosphate compound suitable for studies of energy homeostasis, enzymatic regulation of carbohydrate metabolism, and inflammatory signaling pathways. The APExBIO product information provides detailed handling and storage guidelines. Using such reagents in parallel with PEP-based workflows may support the dissection of metabolic-inflammation interfaces in tissue injury, neurodegeneration, and cardiovascular ischemia models.